Status:
TERMINATED
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
Lead Sponsor:
Duke University
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Sarcoma, Soft Tissue
Osteosarcoma
Eligibility:
All Genders
18-82 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood. Sometimes, thrombocy...
Detailed Description
The combination chemotherapy regimen of gemcitabine and docetaxel has become an increasingly used treatment choice for subjects with advanced sarcomas. The regimen has shown activity in first and seco...
Eligibility Criteria
Inclusion
- Metastatic soft tissue or bone sarcoma
- 18 years of age or older
- Adequate blood counts
- Adequate kidney and liver function
- At least 1 but no more than 3 prior systemic therapy regimens for this cancer
- Good performance status - able to carry out work of a light or sedentary nature
Exclusion
- Pre-existing hear disease such as congestive heart failure, or arrhythmia known to increase the risk of thromboembolic events (blood clots)
- Blood clot in the last 6 months, known clotting problem or platelet disorder
- History of brain cancer
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01491594
Start Date
April 1 2012
End Date
March 1 2013
Last Update
April 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Cancer Center
Durham, North Carolina, United States, 27710